Variant Submission Sunset (April Fools’ Post)

A Separation of Powers: The Case Against CGA Review of Custom Variant Submissions

In the high-stakes world of clinical genomics, the Clinical Genetic Analyst (CGA) acts as the ultimate gatekeeper between raw sequencing data and life-altering medical reports. Their role is defined by precision, adherence to standardized guidelines (such as the ACMG/AMP criteria), and clinical objectivity. However, as personalized medicine expands, there is increasing pressure for labs to accept "custom variant submissions"—interpretations or specific variants flagged by external researchers or clinicians that may not meet standard laboratory thresholds.

While the desire to incorporate every possible lead is understandable, tasking CGAs with the review of these custom submissions is a strategic mistake. It threatens the integrity of the clinical pipeline, introduces significant liability, and compromises the objectivity essential to diagnostic medicine.

1. The Conflict of Standardization vs. Subjectivity

The backbone of clinical genomics is reproducibility. CGAs operate within a framework designed to ensure that a variant classified as "Likely Pathogenic" in one lab would be viewed similarly in another. Custom submissions, by their very nature, often bypass this rigor. They are frequently based on:

• In-house research data that has not been peer-reviewed.

• Anecdotal "clinical intuition" from a treating physician.

• Functional assays that lack clinical validation.

When a CGA is asked to review these, they are forced to step out of the "Standard Operating Procedure" (SOP) and into the scientific Wild West. Attempting to reconcile a researcher’s "gut feeling" with strict clinical criteria creates a cognitive dissonance that slows down the pipeline and introduces dangerous levels of subjectivity into a process that demands absolute consistency.

2. The Burden of Liability and "The Signed Name"

In a clinical setting, the CGA (and the signing director) bears the legal and ethical responsibility for the report. If a CGA approves a custom variant based on external data they cannot personally verify, they are essentially "signing off" on someone else’s homework.

If that "custom" evidence later proves to be a false positive, the liability rests with the clinical lab, not the external researcher who submitted the suggestion. Expecting CGAs to vet external data—without the same access to the primary raw data or the experimental environment where it was produced—places them in an untenable position. It asks them to vouch for the unknown.

3. Resource Allocation and the "Research Rabbit Hole"

Clinical labs are already facing a massive bottleneck in data interpretation. CGAs are highly trained professionals whose time is best spent navigating validated clinical databases and internal cohorts.

Reviewing custom submissions is notoriously time-consuming. It often requires:

• Extensive back-and-forth communication with the submitter.

• Manual searching of obscure literature to find the "missing link" the submitter claims exists.

• Re-analyzing data outside of the automated bioinformatics pipeline.

Diverting CGA resources to these "boutique" reviews reduces the laboratory's overall throughput, ultimately delaying results for the vast majority of patients whose cases follow standard diagnostic paths.

4. Preservation of Clinical Objectivity

There is a subtle but real psychological pressure involved in custom submissions. When a clinician or researcher submits a specific variant they "believe" is the cause of a patient's disease, it creates a confirmation bias.

The CGA’s role is to be a skeptical observer. By forcing them to engage with these pre-selected "interesting" variants, the lab risks turning the analyst from an objective judge into a proofreader for the submitter’s hypothesis. To maintain the "blinded" integrity of clinical classification, the analysis should remain independent of external expectations.

Conclusion

The bridge between research and the clinic is vital, but the Clinical Genetic Analyst is not the proper vehicle for that crossing. To protect the quality of clinical reports and the mental bandwidth of the analysts, custom variant submissions should be handled by a dedicated Research-to-Clinic Liaison or an independent Review Board.

By keeping CGAs focused on standardized, validated data, labs ensure that clinical reports remain the "gold standard" of truth, rather than a collection of unverified scientific leads. The integrity of the diagnostic report depends not on how much information we include, but on the rigorous quality of what we allow to pass the gate.